Clinical Trial Update: Imatinib Mesylate and Hydroxyurea in Treating Patients With Recurrent or Progressive Meningioma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update evaluating imatinib mesylate in combination with hydroxyurea for patients with recurrent or progressive glioblastoma or gliosarcom…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma
• Gliosarcoma

Drugs mentioned

• HYDROXYUREA (Hydroxyurea)
• Imatinib mesylate (Imatinib)

Snippet

Sponsor: Duke University | Conditions: Glioblastoma, Gliosarcoma | Phase 2 | Status: COMPLETED | Results posted: 2013-01-14